Alpha 4 beta 7 integrin modulators and uses thereof

A novel small molecule inhibitor targeting alpha 4 beta 7 integrin, represented by Formula (I), addresses the limitations of current IBD treatments by providing oral bioavailability and reduced side effects, achieving effective anti-inflammatory outcomes for UC and CD.

WO2025106410A1 Publication Date: 2025-05-22DICE MOLECULES SV INC
8 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/055478
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-15
Filing Date
2024-11-12
Publication Date
2025-05-22

AI Technical Summary

Technical Problem

Current treatments for inflammatory bowel diseases (IBD) like ulcerative colitis (UC) and Crohn’s disease (CD) are limited by the need for parenteral administration and are associated with significant side effects due to the long half-life of existing therapies such as ENTYVIO (vedolizumab).

Method used

Development of a compound represented by Formula (I), which is a small molecule inhibitor selective for alpha 4 beta 7 integrin, designed to be orally bioavailable and reduce side effects by mimicking the anti-inflammatory actions of ENTYVIO with high selectivity over alpha 4 beta 1 integrin.

Benefits of technology

The compound achieves significant anti-inflammatory effects and reduces symptoms of IBD with improved bioavailability and reduced side effects compared to existing therapies, offering a more convenient oral administration route.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure provides small molecule compounds and pharmaceutical compositions for the modulation of alpha 4 beta 7 integrin, useful for the treatment of inflammatory conditions such as inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
Need to check novelty before this filing date? Find Prior Art